RxDoctor Payments Data

Nicole Douthat, DO

Internal Medicine · Lexington, KYNPI 1700381928

Payments from drug & device makers

$4,748in general payments, 2019–2025

Across 272 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$865
  • Pfizer$514
  • Novo Nordisk$480
  • Esperion Therapeutics, Inc.$333
  • Boehringer Ingelheim$293
  • AbbVie$280
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,736100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,748 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,427
Medicare patients
95
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$63,458
EliquisApixaban46$39,551
MounjaroTirzepatide32$32,569
JardianceEmpagliflozin20$23,130
TrulicityDulaglutide14$21,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,016
NexletolBempedoic Acid12$10,119
Breo ElliptaFluticasone/Vilanterol16$7,161
Rosuvastatin Calcium109$1,841
Levothyroxine Sodium143$1,428
Atorvastatin Calcium146$1,387
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,367
Albuterol Sulfate HfaAlbuterol Sulfate53$1,236
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,048
Esomeprazole Magnesium18$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$480$63,45855 claims
Lilly USA, LLCMounjaro, Trulicity$865$53,94446 claims
PfizerEliquis$514$39,55146 claims
Boehringer IngelheimJardiance$293$23,13020 claims
GSKTrelegy Ellipta, Breo Ellipta$162$20,17839 claims
Esperion Therapeutics, Inc.Nexletol$333$10,11912 claims
AbbVieSynthroid, Armour Thyroid$280$1,37129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →